ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0393

Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA

Marianne Kerski1, Smriti Mohan1, Cynthia Vizcaya2, Reema Sutariya3, Weibin Bao3 and Matthew Stoll4, 1University of Michigan, Ann Arbor, MI, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2024

Keywords: Biologicals, Juvenile Inflammatory Arthritis, Pediatric rheumatology, Temporomandibular joint

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on quality of life as its use is required for daily functions such as talking and eating. Untreated TMJ inflammation in children can lead to growth abnormalities leading to permanent facial deformities. Little is known about the effectiveness of different types of systemic therapies for the treatment of TMJ arthritis as no prospective studies have been performed in the biologic era. The current study is a secondary data analysis of the open label portion of the JUNIPERA trial, a prospective study evaluating the efficacy of secukinumab in patients with juvenile enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). The objective is to evaluate the efficacy of secukinumab in treating TMJ involvement in children with ERA and JPsA.

Methods: Biologic naïve patients with ERA (age 4 – 17 years) and JPsA (age 2 – 17 years) enrolled in the JUNIPERA trial began subcutaneous secukinumab (75/150 mg in patients < 50/≥50 kg). All patients received doses at week 0, 1, 2, 3, 4, 8, and 12 as part of the open label portion of the trial. Disease assessment measures including 27-joint Juvenile Arthritis Disease Activity Score (JADAS-27), physician global assessment, and patient global assessment were recorded at each visit. TMJ involvement was defined as having joint tenderness, joint swelling, or limitation of motion. A repeated measure logistic regression (RMLR) was used to assess proportion of patients with TMJ involvement at each timepoint through week 12.

Results: A total of 86 patients with JIA (52 with ERA and 34 with JPsA) were enrolled and 28 patients had TMJ involvement at week 0 (32.6%).  All but two patients had TMJ assessments up to week 12 on secukinumab. Baseline demographics and disease activity measures in patients with and without TMJ involvement are summarized in Table 1. Patients with TMJ involvement were more likely to be female and were older than those without. The physician global assessment trended towards (p=0.05) having a higher score in patients with TMJ involvement compared to those without. The two groups had no statistically significant differences in JADAS-27 or patient global assessment. The effectiveness of secukinumab on TMJ involvement is shown in Figure 1. RMLR demonstrated a statistically significant trend in reduced proportions of patients with TMJ involvement through week 12 (p=0.0005).

Conclusion: Studies on the treatment of TMJ arthritis are limited given the challenges in differentiating TMJ arthritis from dysfunction without use of imaging. The current post-hoc analysis demonstrates secukinumab  improved signs and symptoms of TMJ involvement in patients with ERA and JPsA. Additional prospective studies are needed to compare the efficacy of systemic therapies in treating TMJ arthritis to reduce permanent damage from undertreated TMJ arthritis using imaging as an endpoint.

Supporting image 1

Table 1. Demographics and disease activity measures in patients with and without TMJ involvement at baseline (week 0).

Supporting image 2

Figure 1: Proportion of patients with TMJ involvement at each study time point. RMLR demonstrates statistically significant reduction in the proportion of patients with TMJ involvement with secukinumab treatment.


Disclosures: M. Kerski: None; S. Mohan: None; C. Vizcaya: Novartis, 3, 11; R. Sutariya: Novartis, 3, 8; W. Bao: Novartis, 3, 11; M. Stoll: None.

To cite this abstract in AMA style:

Kerski M, Mohan S, Vizcaya C, Sutariya R, Bao W, Stoll M. Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/effectiveness-of-secukinumab-in-tmj-symptoms-in-children-with-jpsa-and-era-a-secondary-data-analysis-of-junipera/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-secukinumab-in-tmj-symptoms-in-children-with-jpsa-and-era-a-secondary-data-analysis-of-junipera/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology